AXA PPP enhances prostate cancer diagnosis pathway

Find out more
Blog | AXA PPP enhances prostate cancer diagnosis pathway

AXA PPP healthcare has teamed up with screening service, Check4Cancer, to enhance its prostate cancer diagnosis pathway. The new screening process will help fast-track members with suspected prostate cancer so that they undergo a detailed MRI of the prostate before undergoing a biopsy.

Available to its individual, SME and large corporate members, the new approach avoids the invasive routine of taking small samples of tissues for analysis via needle insertion into the prostate gland through the wall of the rectum, which misses cancer 50% of the time and can often lead to infection.

Read article in Cover magazine

Prostate cancer is the most common cancer in men and, according to Prostate Cancer UK, one in eight diagnosed at some point in their lives.

The new screening process, which can also help fast-track cases where members are concerned about skin or breast cancer, will mean those with suspected prostate cancer - as of 26 November - can undergo a detailed MRI of the prostate before undergoing a biopsy.

The evidence for the diagnostic pathway was uncovered during a PROMIS trial published in 2017, which found that almost 30% of men would have been able to avoid having a biopsy if the scan was normal.

"It was a pleasure to work with such an enthusiastic and expert team and this is without doubt the first of its kind for men with private medical insurance (PMI)," said Professor Richard Hindley, who was involved with the design of the pathway and the PROMIS trial. "Patients will now be directed to see expert urologists who are able to see patients in a timely manner and provide the highest quality standard of biopsy when required after a multi-parametric MRI."

 Fast-track

Additionally, from 1 January 2019, any individual, SME or large corporate member of AXA PPP who experiences signs or symptoms of skin cancer need not wait to see their GP - and wait for a GP referral.

The health insurer is also making this approach available to members of large corporate schemes who suspect they may have breast cancer from 1 January 2019.

Sarah Taylor, AXA PPP healthcare's head of specialist and practitioner relations said: "Not knowing is worrying. Waiting makes it worse. If you're concerned by prostate, skin or breast cancer the chances are you'll be relieved to know that you have quick access to diagnosis and medical support, at a time and place that's convenient to you, should you need it. We're confident that our members will find the options we're introducing for cancer diagnosis and care reassuring at what can be a troubling time in their lives."

richard hindley avatar image

Professor Richard Hindley

Clinical Advisor for Prostate Cancer

Consultant Urologist at Hampshire Hospitals. Visiting Professor at the department of Health & Wellbeing at the University of Winchester Richard Hindley is a Consultant Urologist at Hampshire Hospitals and was appointed in 2014. In 2017 he was awarded a visiting Professor position working with the Department of Health and Wellbeing at the University of Winchester. This was in recognition of his growing prostate research portfolio which includes collaborating with other units including UCLH and the University of Oxford. He was privileged to be involved with the PROMIS and PRECISION trials, which have changed forever the diagnostic pathway for men with suspected prostate cancer. He has publications in both the Lancet at the NEJM. His interests relate not only to prostate cancer diagnostics but also focal therapy as a treatment option for men with intermediate risk prostate cancer, as well as minimally invasive treatments for benign prostatic obstruction and men’s health issues in general.

Find out more

Knowledge and support

Go to all articles
Leading the Way in Cancer Risk Stratification and Screening

Leading the Way in Cancer Risk Stratification and Screening

From advanced screening techniques to innovative risk stratification tools, here's how we are actively shaping the future of cancer care.

Read more
Professor Andrew Beggs Honoured with the Josiah Mason Award for Academic Achievement

Professor Andrew Beggs Honoured with the Josiah Mason Award for Academic Achievement

Check4Cancer is proud to congratulate Professor Andrew Beggs, Clinical Advisor to Check4Cancer, on receiving the prestigious Josiah Mason Award for...

Read more
Dr Haider Raza Joins Check4Cancer to Advance AI-Powered Skin Cancer Detection

Dr Haider Raza Joins Check4Cancer to Advance AI-Powered Skin Cancer Detection

Check4Cancer is thrilled to announce the appointment of Dr Haider Raza to its Clinical Advisory Board.

Read more